Valor202020212022202320242025TTMGastos comerciales, generales y administrativos317.88 M282.66 M451.42 M481.87 M557.87 M491.72 M491.72 MInvestigación y desarrollo722.34 M771.18 M877.09 M877.39 M804.52 M1.52 B1.52 BBeneficio operativo-564.16 M-459.71 M-536.2 M-267.82 M218.08 M-699.78 M-699.78 MTotal de ingresos no operativos11.1 M40.76 M-153.76 M-252.27 M42.69 M-2.44 M-2.44 MGastos por intereses, netos de intereses capitalizados59.95 M63.52 M53.25 M22.01 M-18.39 M-38.14 M-32.48 MIngresos no operativos, una vez deducidos los gastos por intereses-49.37 M-21.83 M-171.99 M-307.34 M18.39 M55 M49.34 MIngresos/gastos extraordinarios517 K-936 K-35.02 M33.05 M42.69 M-19.31 M-19.31 MBeneficio antes de impuestos-553.07 M-418.95 M-689.96 M-520.1 M260.77 M-702.23 M-702.23 MParticipación en los beneficios————00—Impuestos1.06 M-168 K13.53 M15.88 M25.54 M11.19 M11.19 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos470 K-7.62 M9.64 M-37 K-2.13 M-7.05 M-7.05 MBeneficio neto antes de actividades interrumpidas-554.13 M-418.78 M-703.49 M-535.98 M235.24 M-713.41 M-842.79 MOperaciones suspendidas———————Beneficio neto-554.13 M-418.78 M-703.49 M-535.98 M235.24 M-713.41 M-842.79 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-554.13 M-418.78 M-703.49 M-535.98 M252.24 M-713.41 M-713.41 MBeneficio básico por acción——-8.03-5.82.47-7.13-8.32Beneficio por acción diluido-7.11-5.15-8.03-5.82.34-7.13-8.44Número medio de acciones ordinarias77.96 M81.26 M87.56 M92.4 M95.08 M100.12 M395.72 MAcciones diluidas77.96 M81.26 M87.56 M92.4 M107.88 M100.12 M404.34 MEBITDA-537.25 M-421.69 M-494.34 M-223.43 M255.81 M-655.26 M-655.26 MEBIT-564.16 M-459.71 M-536.2 M-267.82 M218.08 M-699.78 M-699.78 MCosto de los ingresos—————25.5 M—Otros costes de producción—————165.3 M—Amortización y depreciación (flujo de caja)26.91 M38.02 M41.86 M44.4 M37.72 M44.52 M44.52 M
Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.